Scott McKnight, MD
Colon & Rectal Surgery · Houston, TXNPI 1316151137
Payments from drug & device makers
What this record shows
This record is dominated by education: $44,000 of the $72,889 with a category attached, or 60.4%. Intuitive Surgical accounts for 93.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $23,910 and has fallen 73.3% since, to $6,387 in 2025. Among colon & rectal surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $470.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$68K
- Medtronic$1K
- THD America, Inc.$706
- Johnson & Johnson$428
- Pacira Pharmaceuticals Incorporated$377
- Baxter Healthcare$348
- plus $2K from 22 others
What the payments were for
- Consulting fees$8751%
- Speaking & faculty fees$15,07521%
- Travel & lodging$4,6156%
- Food & beverage$8,32411%
- Education$44,00060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 104 | $68,325 |
| Medtronic | 4 | $1,032 |
| THD America, Inc. | 5 | $706 |
| Johnson & Johnson | 5 | $428 |
| Pacira Pharmaceuticals Incorporated | 4 | $377 |
| Baxter Healthcare | 4 | $348 |
| BD | 1 | $202 |
| Aroa Biosurgery Incorporated | 1 | $167 |
| TELA Bio, Inc. | 3 | $151 |
| Stryker | 1 | $142 |
| Davol Inc. | 1 | $140 |
| Edwards Lifesciences | 1 | $134 |
| Genentech USA, Inc. | 2 | $125 |
| Shire North American Group Inc | 1 | $106 |
| Convatec Inc. | 1 | $105 |
| Covidien LP | 1 | $75 |
| Conmed Corporation | 1 | $45 |
| BK Medical Holding Company Inc. | 1 | $43 |
| Baudax Bio Inc. | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Axonics, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Smith+Nephew | 1 | $27 |
| Acell, Inc. | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $12 |
| Kerecis Limited | 1 | $11 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$65,748
- DA VINCI SP$456
- EXPAREL$353
- Palindrome$325
- PerClot$272
- Echelon Flex$264
- HemoSphere$202
- SPY TECHNOLOGY$142
- ARISTA AH FLEXITIP$140
- SmartAblateTM System RF Generator$138
- ClearSight System$134
- LigaSure$124
- ECHELON FLEX Stapler$114
- Echelon Powered Circular$114
- Surgicel Powder$114
- GATTEX$106
- AQUACEL Ag Extra$105
- Lucentis$102
How this compares
$72,889 in reported general payments places this provider in the 90th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 25 | $2,286 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,903 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 12 | $854 |
| Neomycin Sulfate | 44 | $230 |
| Hydrocortisone | 12 | $185 |
| Tramadol Hcl | 45 | $148 |
| Gabapentin | 25 | $129 |
| Metronidazole | 46 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $36 | $1,90311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 200 colon & rectal surgery providers in Texas.
Other colon & rectal surgery in Houston
- Diego Marines CopadoHouston$462K
- Erik AskenasyHouston$142K
- Eric HaasHouston$140K
- Theodoros VoloyiannisHouston$100K
- Tsuyoshi KonishiHouston$68K
- Jean-Paul LefaveHouston$47K
- George ChangHouston$31K
- Michael SnyderHouston$24K
- Marianne CusickHouston$22K
- Joshua CourseyHouston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.